FDA Approved: NORVASC — Supplemental Application (Viatris Specialty LLC)

View source ↗

Summary

The FDA approved a supplemental application for NORVASC (amlodipine besylate) by Viatris Specialty LLC, resulting in changes to the labeling of the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Coronary Artery Disease
• Hypertension

Drugs mentioned

• NORVASC (amlodipine besylate)

Snippet

SUPPL AP for NORVASC (AMLODIPINE BESYLATE)